脓毒性休克患者早期与晚期去甲肾上腺素给药的比较:系统评价与Meta分析
该系统评价与Meta分析检索PubMed、EMBASE、Cochrane Library和KMbase数据库,纳入12项研究(4项随机对照试验和8项观察性研究)共7281例成年脓毒症患者,按特定时间点或去甲肾上腺素使用方案差异分为早期组和晚期组。主要终点总体死亡率在随机对照试验(OR 0.70,95%CI 0.41-1.19)和观察性研究(OR 0.83,95%CI 0.54-1.29)中均无显著差异。在两项未采用限制性液体策略(优先使用血管加压药并减少静脉液体量)的随机对照试验中,早期去甲肾上腺素组死亡率显著低于晚期组(OR 0.49,95%CI 0.25-0.96)。早期组在观察性研究中无机械通气天数更多(均数差4.06,95%CI 2.82-5.30),三项报告肺水肿的随机对照试验中肺水肿发生率更低(OR 0.43,95%CI 0.25-0.74),其他次要终点无差异。
要点
- 12项研究(4项RCT和8项观察性研究)共7281例成年脓毒症患者,早期与晚期去甲肾上腺素总体死亡率无显著差异(RCT:OR 0.70,95%CI 0.41-1.19;观察性研究:OR 0.83,95%CI 0.54-1.29)。
- 在两项未采用限制性液体策略(优先血管加压药并减少静脉液体量)的RCT中,早期去甲肾上腺素组死亡率显著低于晚期组(OR 0.49,95%CI 0.25-0.96)。
- 三项报告肺水肿的RCT中,早期去甲肾上腺素组肺水肿发生率更低(OR 0.43,95%CI 0.25-0.74)。
- 观察性研究中早期去甲肾上腺素组无机械通气天数更多(均数差4.06,95%CI 2.82-5.30)。
- 其他次要终点(ICU住院时间、无肾替代治疗天数、无血管加压药天数、不良事件、总液体量)无差异。
适用人群与场景
- 成年脓毒症患者,根据特定时间点或去甲肾上腺素使用方案差异分为早期去甲肾上腺素组和晚期去甲肾上腺素组。
研究设计与关键结果
- 研究类型为系统评价与Meta分析,纳入12项研究(4项随机对照试验和8项观察性研究),共7281例患者。
- 主要终点总体死亡率:随机对照试验中早期去甲肾上腺素组与晚期组无显著差异(OR 0.70,95%CI 0.41-1.19);观察性研究中两组无显著差异(OR 0.83,95%CI 0.54-1.29)。
- 在两项未采用限制性液体策略(优先使用血管加压药并减少静脉液体量)的随机对照试验中,早期去甲肾上腺素组死亡率显著低于晚期组(OR 0.49,95%CI 0.25-0.96)。
- 观察性研究中早期去甲肾上腺素组无机械通气天数更多(均数差4.06,95%CI 2.82-5.30)。
- 三项报告肺水肿的随机对照试验中,早期去甲肾上腺素组肺水肿发生率更低(OR 0.43,95%CI 0.25-0.74)。
- 其他次要终点(ICU住院时间、无肾替代治疗天数、无血管加压药天数、不良事件、总液体量)无差异。
证据类型、等级与局限
- 证据类型为系统评价与Meta分析,纳入4项随机对照试验和8项观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于脓毒性休克患者,早期与晚期去甲肾上腺素给药对总体死亡率无显著差异,但早期给药似乎降低肺水肿发生率。
- 在未采用限制性液体策略(优先血管加压药并减少静脉液体量)的研究中,早期去甲肾上腺素使用与死亡率改善相关,作者认为这支持早期使用去甲肾上腺素。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Vasopressor administration at an appropriate time is crucial, but the optimal timing remains controversial.
RESEARCH QUESTION: Does early vs late norepinephrine administration impact the prognosis of septic shock?
STUDY DESIGN AND METHODS: Searches were conducted in PubMed, EMBASE, the Cochrane Library, and KMbase databases. We included studies of adults with sepsis and categorized patients into an early and late norepinephrine group according to specific time points or differences in norepinephrine use protocols. The primary outcome was overall mortality. The secondary outcomes included length of stay in the ICU, days free from ventilator use, days free from renal replacement therapy, days free from vasopressor use, adverse events, and total fluid volume.
RESULTS: Twelve studies (four randomized controlled trials [RCTs] and eight observational studies) comprising 7,281 patients were analyzed. For overall mortality, no significant difference was found between the early norepinephrine group and late norepinephrine group in RCTs (OR, 0.70; 95% CI, 0.41-1.19) or observational studies (OR, 0.83; 95% CI, 0.54-1.29). In the two RCTs without a restrictive fluid strategy that prioritized vasopressors and lower IV fluid volumes, the early norepinephrine group showed significantly lower mortality than the late norepinephrine group (OR, 0.49; 95%, CI, 0.25-0.96). The early norepinephrine group demonstrated more mechanical ventilator-free days in observational studies (mean difference, 4.06; 95% CI, 2.82-5.30). The incidence of pulmonary edema was lower in the early norepinephrine group in the three RCTs that reported this outcome (OR, 0.43; 95% CI, 0.25-0.74). No differences were found in the other secondary outcomes.
INTERPRETATION: Overall mortality did not differ significantly between early and late norepinephrine administration for septic shock. However, early norepinephrine administration seemed to reduce pulmonary edema incidence, and mortality improvement was observed in studies without fluid restriction interventions, favoring early norepinephrine use.
参考来源
- Ahn C, Yu G, Shin TG, et al. Comparison of Early and Late Norepinephrine Administration in Patients With Septic Shock: A Systematic Review and Meta-Analysis. Chest. 2024. PMID: 38972348. doi:10.1016/j.chest.2024.05.042
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。